Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2017 Jul;31(7):571-583.
doi: 10.1007/s40263-017-0446-8.

Ascorbic Acid to Manage Psychiatric Disorders

Affiliations
Review

Ascorbic Acid to Manage Psychiatric Disorders

Morgana Moretti et al. CNS Drugs. 2017 Jul.

Abstract

Ascorbate has critical roles in the central nervous system (CNS); it is a neuromodulator of glutamatergic, cholinergic, dopaminergic, and γ-aminobutyric acid (GABA)-ergic neurotransmission, provides support and structure to neurons, and participates in processes such as differentiation, maturation, and survival of neurons. Over the past decade, antioxidant properties of ascorbate have been extensively characterized and now it is known that this compound is highly concentrated in the brain and neuroendocrine tissues. All this information raised the hypothesis that ascorbate may be involved in neurological disorders. Indeed, the biological mechanisms of ascorbate in health and disease and its involvement in homeostasis of the CNS have been the subject of extensive research. In particular, evidence for an association of this vitamin with schizophrenia, major depressive disorder, and bipolar disorder has been provided. Considering that conventional pharmacotherapy for the treatment of these neuropathologies has important limitations, this review aims to explore basic and human studies that implicate ascorbic acid as a potential therapeutic strategy. Possible mechanisms involved in the beneficial effects of ascorbic acid for the management of psychiatric disorders are also discussed.

PubMed Disclaimer

References

    1. Brain Res. 1990 Dec 24;537(1-2):328-32 - PubMed
    1. Prog Neuropsychopharmacol Biol Psychiatry. 2011 Apr 29;35(3):676-92 - PubMed
    1. Int J Vitam Nutr Res. 2014;84(1-2):12-7 - PubMed
    1. Neuropharmacology. 2012 Jan;62(1):35-41 - PubMed
    1. Neurochem Int. 1983;5(6):773-8 - PubMed

LinkOut - more resources